Recent News

• 05.14.2025 - Affimed Announces Receipt of Nasdaq Delisting Notice
• 05.14.2025 - Affimed Announces Receipt of Nasdaq Delisting Notice
• 05.13.2025 - Affimed Announces Filing for the Opening of Insolvency Proceedings
• 05.13.2025 - Affimed Announces Filing for the Opening of Insolvency Proceedings
• 04.23.2025 - Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
• 04.23.2025 - Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
• 04.21.2025 - Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
• 03.25.2025 - Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
• 03.25.2025 - Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
• 03.03.2025 - Affimed to Present at the Leerink Partners Global Healthcare Conference 2025

Recent Filings

• 05.14.2025 - EX-99.1 EX-99.1
• 05.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.13.2025 - EX-99.1 EX-99.1
• 05.01.2025 - NT 20-F Notification of inability to timely file Form 20-F
• 04.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.21.2025 - EX-99.1 EX-99.1
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors